Watchlist Price Alert

Quanterix Corporation (QTRX)

NASDAQ: QTRX · Real-Time Price · USD

5.21

-0.03 (-0.48%)

At close: May 30, 2025, 3:59 PM

5.20

-0.10%

After-hours: May 30, 2025, 04:04 PM EDT

-0.48% (1D)

Bid	4.05
Market Cap	202.11M
Revenue (ttm)	135.29M
Net Income (ttm)	-49.96M
EPS (ttm)	-1.24
PE Ratio (ttm)	-4.2
Forward PE	-4.98
Analyst	Buy

Ask	5.2
Volume	380,641
Avg. Volume (20D)	756,683
Open	5.16
Previous Close	5.24
Day's Range	5.00 - 5.29
52-Week Range	4.05 - 19.18
Beta	1.11

About QTRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol QTRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for QTRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

-1.79%

Quanterix Corporation shares are trading lower aft... Unlock content with Pro Subscription

6 months ago

-18.26%

Quanterix shares are trading lower. The company reported Q3 financial results.

News

2 weeks ago · seekingalpha.com

Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript

Quanterix Corporation (NASDAQ:QTRX ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Joshua Young - Head, IR Masoud Toloue - President and CEO Vandana Sriram - CFO Confer...

2 weeks ago · zacks.com

Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.26 per share a year ago.

3 weeks ago · businesswire.com

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Bioscience...

3 weeks ago · businesswire.com

Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen...

1 month ago · businesswire.com

Quanterix and Akoya Biosciences Announce Amended Merger Agreement

BILLERICA, Mass. & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences ...

1 month ago · businesswire.com

Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders

RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QT...

1 month ago · businesswire.com

Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences

CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (“Quanterix”...

1 month ago · businesswire.com

Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya

RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) is a holder of approximately 7.5% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: ...